Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of JTT-751 (Ferric Citrate Hydrate) in Iron Deficiency Anemia
jRCT2080223943Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric citrate in iron deficiency anemia (IDA), sponsored by Japan Tobacco. Primary endpoints: Efficacy of JTT-751 and Safety of JTT-751. Started Jun 2018; status: completed.
02
Drugs
ferric citrate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on jRCT2080223943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223943.